C3 Glomerulopathy (C3G)
Nephrology·MeSH: Glomerulonephritis, Membranoproliferative
Prevalence
0.5 / 100K
3 drugs in development·3 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(2)
Phase 4(1)
| Drug | Company |
|---|---|
| Avacopan | AMGEN INC (AMGN) |
Compare drugs
Frequently asked questions
How many drugs are in development for C3 Glomerulopathy (C3G)?
BioSniper tracks 3 drugs in development for C3 Glomerulopathy (C3G) across 3 companies.
How many clinical trials target C3 Glomerulopathy (C3G)?
There are 1 clinical trial targeting C3 Glomerulopathy (C3G) tracked by BioSniper.
What is the prevalence of C3 Glomerulopathy (C3G)?
The estimated prevalence of C3 Glomerulopathy (C3G) is approximately 0.5 per 100,000 population.
Deep-dive into C3 Glomerulopathy (C3G)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis